The effect of zoledronate during bone healing
Tóm tắt
Bisphosphonates have become the treatment of choice for a variety of bone diseases in which excessive osteoclastic activity is an important pathologic feature. However, inhibition of osteoclastic activity could lead to inhibition of remodeling during bone healing or repair. The objective of this study is to investigate the effect of zoledronate (the most potent bisphosphonate) in the biological process of bone healing.
Thirty immature male rabbits were divided into two groups (control and experimental) of 15 animals each. Both groups were submitted to fibular osteotomy. Only in the experimental group a single dose of zoledronate was administered. After 1, 2, and 4 weeks, animals of both groups were euthanized and the osteotomy site was histomorphometrically evaluated. The associated parameters analyzed were tissue volume (TV), fractional trabecular bone volume (BV/TV), fractional woven bone volume (WoV/TV), fractional periosteal fibrous volume (FbV/TV), and medullary fibrous volume (MaV/TV).
The first week of healing was characterized by small callus area (experimental group) and less periosteal fibrosis. The second week was characterized by a large quantity of woven bone and marked decrease in periosteal fibrosis in the two groups. In the control group there was also a significant increase in trabecular bone. The fourth week was characterized by increased amount of woven bone and trabecular bone in the experimental group; there was increased medullary fibrosis in the two groups, while there continued to be significantly less periosteal fibrosis in the experimental group.
Zoledronate does not prevent bone healing. However, the effect of zoledronate was characterized by accentuated stimulation of primary bone production and probably inhibition of remodeling, leading to retention of trabecular bone.
Từ khóa
Tài liệu tham khảo
Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporosis Int 9:566–580
Madsen JE, Berg-Larsen T, Kirkeby OJ, Falch JA, Nordsletten L (1998) No adverse effects of clodronate on fracyure healing in rats. Acta Orthop Scand 69:532–536
Li J, Mori S, Kaji Y, Kawanishi J, Akiyama T, Norimatsu H (2000) Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. J Bone Miner Res 15:2240–2251
Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA (1996) Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14:79–84
Kiely P, Ward K, Bellamore MC, Briody J, Cowell CT, Little DG (2007) Bisphosphonate rescue in distraction osteogenesis: a case series. J Pediatr Orthop 27(4):467–471
Matos MA, Araújo FP, Paixão FB (2007) The effect of zoledronate on bone remodeling during the healing process. Acta Cir Bras 22:115–119
Matos MA, Gonçalves RR, Araújo FP (2001) Experimental model for osteotomy in immature rabbit. Acta Ortop Bras 9(4):21–26
Matos MA, Araújo FP, Paixão FB (2008) Histomorphometric evaluation of bone healing in rabbit fibular odteotomy model without fixation. J Orthop Surg Res 29(3):4
Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry. Standardization of nomeclature, symbols and units. J Bone and Miner Res 2:595–610
Little DG, Ramachandran M, Schindeler A (2007) The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br 9(4):425–433
Deckers MM, Van Beek ER, Van Der Pluijim G, Wetterwald A, Van Der Wee-Pals L, Cecchini MG, Papapoulos SE, Löwik CW (2002) Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 17:998–1007
Goodship AE, Walker PC, McNally D, Chambers T, Green JR (1994) Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bon. Ann Oncol 5(Suppl 7):S53–S55
Amanat N, Mcdonald M, Godfrey C, Bilston L, Little D (2007) Optimal timing of bolus intravenous zoledronic acid in a rat fracture model. J Bone Miner Res 22(6):867–876
McDonald MM, Dulai SK, Godfrey C, Sztynda T, Little DG (2008) Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone 43(4):653–662
Little DG, McDonald M, Bransford R, Hodfrey CB, Amanat N (2005) Manipulation of the anabolic and catabolic reponses with OP-1 and zoledronic acid in a rat clinical defect model. J Bone Miner Res 20:2044–2052
Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanism downstream of extracellular signal-regulated kinase activation. J Biol Chem 280(8):7317–7325
Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104(10):1363–1374